Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 6 Tiantan Xi Li, Dongcheng District, Beijing, 100050, People's Republic of China.
J Neurooncol. 2013 Oct;115(1):53-9. doi: 10.1007/s11060-013-1193-4. Epub 2013 Jul 4.
Central nervous system hemangiopericytoma (HPC) is a malignant vascularized mesenchymal tumor with a high rate of recurrence. Because of its rarity, few clinical characteristics and prognostic analysis information regarding recurrent HPC exist for doctors to pursue optimal outcomes. Forty-six recurrent HPC cases treated at our hospital between 2004 and 2012 were compiled into a single database based on a retrospective review of patient records, which were used to summarize the clinical characteristics. The mean survival of the recurrent HPC patients in our cohort was 41.6 ± 4.4 months, with 1-, 2-, 3-, and 4-year survival rates of 80.4, 65.2, 59.2, and 53.8 %, respectively. Thirty patients (65.2 %) suffered their first tumor recurrence, with a mean survival of 36.9 ± 4.1 months. Sixteen patients (34.8 %) suffered a second or further tumor recurrence, with a mean survival of 39.7 ± 7.0 months. Eighteen patients (39.1 %) died of all causes during the follow-up period, with a mean survival of 14.2 ± 5.6 months. Univariate and multivariate regression analyses showed that factors associated with good prognosis included recurrence age over 35 years, an interval between the first and second recurrence of more than 1 year and a clear boundary of the recurrent tumor. Gross total resection with adjuvant external beam radiotherapy could independently delay tumor recurrence of the second or more times and prolong the postoperative survival; thus, this strategy should be pursued as the initial treatment.
中枢神经系统血管外皮细胞瘤（HPC）是一种恶性血管间充质肿瘤，复发率高。由于其罕见性，医生在追求最佳治疗效果时，很少有关于复发性 HPC 的临床特征和预后分析信息。我们回顾性地分析了 2004 年至 2012 年期间在我院治疗的 46 例复发性 HPC 患者的病例记录，将其编入单一数据库，以总结临床特征。我们队列中的复发性 HPC 患者的平均生存时间为 41.6±4.4 个月，1、2、3 和 4 年生存率分别为 80.4%、65.2%、59.2%和 53.8%。30 例（65.2%）患者首次肿瘤复发，平均生存时间为 36.9±4.1 个月。16 例（34.8%）患者发生第二次或更多次肿瘤复发，平均生存时间为 39.7±7.0 个月。18 例（39.1%）患者在随访期间因各种原因死亡，平均生存时间为 14.2±5.6 个月。单因素和多因素回归分析表明，与预后良好相关的因素包括复发年龄>35 岁、首次复发和第二次复发之间的间隔>1 年以及复发性肿瘤边界清晰。完全切除肿瘤并辅助外照射放疗可独立延迟第二次或更多次肿瘤复发，并延长术后生存时间；因此，应将这种策略作为初始治疗方法。
